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Purpose: To determine the spectrum and frequency of rhodopsin gene (RHO) mutations in Korean patients with retinitis
pigmentosa (RP) and to characterize genotype–phenotype correlations in patients with mutations.
Methods: The RHO mutations were screened by direct sequencing, and mutation prevalence was measured in patients
and controls. The impact of missense mutations to RP was predicted by segregation analysis, peptide sequence alignment,
and in silico analysis. The severity of disease in patients with the missense mutations was compared by visual acuity,
electroretinography, optical coherence tomography, and kinetic visual field testing.
Results: Five heterozygous mutations were identified in six of 302 probands with RP, including a novel mutation (c.
893C>A, p.A298D) and four known mutations (c.50C>T, p.T17M; c.533A>G, p.Y178C; c.888G>T, p.K296N; and c.
1040C>T, p.P347L). The allele frequency of missense mutations was measured in 114 ethnically matched controls.
p.A298D, newly identified in a sporadic patient, had never been found in controls and was predicted to be pathogenic.
Among the patients with the missense mutations, we observed the most severe phenotype in patients with p.P347L, less
severe phenotypes in patients with p.Y178C or p.A298D, and a relatively moderate phenotype in a patient with p.T17M.
Conclusions: The results reveal the spectrum of RHO mutations in Korean RP patients and clinical features that vary
according to mutations. Our findings will be useful for understanding these genetic spectra and the genotype–phenotype
correlations and will therefore help with predicting disease prognosis and facilitating the development of gene therapy.
Retinitis pigmentosa (RP, OMIM 268000) is the most
common  type  of  inherited  retinal  degeneration  and  is
characterized  by  progressive  degeneration  of  the
photoreceptors.  RP  is  both  clinically  and  genetically
heterogeneous. Clinically, symptoms usually emerge as night
blindness during adolescence, progress to legal blindness by
middle  age,  and  result  in  total  vision  loss  in  later  life.
Epidemiological studies consistently report a frequency of
approximately 1 in 3,000–5,000 individuals, without apparent
ethnic or racial distinctions [1]. However, clinical features,
including age of onset and rate of progression, have been
documented to vary according to genetic background [2].
Therefore, revealing the genotype–phenotype correlations for
the  prognosis  of  RP  patients  as  well  as  identifying  the
causative mutations is of great importance.
Genetically,  RP  can  be  inherited  as  an  autosomal
dominant (adRP), autosomal recessive (arRP), or X-linked
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trait, and sporadic cases represent 40%–50% of all RP patients
[3]. The genetic background of RP patients has not yet been
elucidated owing to a large number of causative genes and
variable inheritance patterns. Most genes for RP cause only a
small proportion of cases, with the exception of the rhodopsin
gene  (RHO,  OMIM  180380),  which  accounts  for
approximately 25% of adRP [4]. The first mutation of RP was
discovered within RHO in 1990 [5], and since then more than
110 mutations have been found in different ethnic groups
[6-10].
The mutation rate of the RHO gene appears to vary with
ethnic background. The rate of RHO mutations is lower in the
Japanese and Chinese population than in the United States
[11,12].  The  first  gene  defect  found  to  cause  RP,  RHO
p.Pro23His, is present in 12% of Caucasian American RP
patients  but  occurs  less  frequently  in  other  ethnic  groups
[11-13]. Although RHO is the most frequently reported adRP
gene in many populations, there are no established data on
RHO mutations in the Korean population. Such data would be
of  great  utility  toward  the  provision  of  effective  genetic
counseling and in predicting disease severity for RP patients.
Here, we present the results of a large-scale molecular
screening of RHO mutations in Korean patients with RP. We
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844describe and characterize the mutations identified in this study
and discuss genotype–phenotype correlations.
METHODS
Subjects: 302 patients (183 males and 119 females, ages 7–86
years) with RP and their family members were recruited from
the  clinic  for  hereditary  retina  degenerations  of  the
Department  of  Ophthalmology,  Seoul  National  University
Hospital (SNUH), Seoul, Korea, and the Korean Retinitis
Pigmentosa Society, a nonprofit support network for Korean
RP patients [14]. Informed consent was obtained from all
participants before enrollment in the study, in accordance with
the protocol approved by the Institutional Review Board at
SNUH and at the Korea National Institute of Health. All
protocols used in this study were also in full accordance with
the tenets of the Declaration of Helsinki. Pedigrees of all
patients were obtained through interviews. adRP was defined
as RP showing direct vertical transmission in at least two
generations with both males and females at equal risk and with
no transmission to offspring of unaffected persons. It was
considered as arRP when more than one member within the
same sibship was affected and no other member of a previous
generation was affected. Sporadic RP was diagnosed when
there was no family history [15]. Among 302 patients included
in  this  study,  the  most  common  inheritance  pattern  was
sporadic RP (182, 60.3%), followed by arRP (55, 18.2%),
adRP  (38,  12.6%),  and  an  unknown  pattern  (27,  8.9%).
Patients with X-linked RP were excluded from the study. A
total of 114 controls (48 males and 66 females, ages 34–70
years) were Korean individuals, recruited from SNUH or the
Korea National Institute of Health, who had normal visual
acuity and normal fundus photographs.
Ophthalmic  examinations:  RP  was  diagnosed  by  retina
specialists at SNUH when a patient showed bilateral retinal
degeneration  with  typical  pigmentation  on  funduscopic
examination  or  rod  dysfunction  on  a  standard
electroretinogram  (ERG)  with  degenerative  retina.
Ophthalmic examination included the best-corrected visual
acuity,  refraction,  intraocular  pressure  measurement,  slit-
lamp  biomicroscopy,  funduscopy,  Goldmann  perimetry,
ERG, and optical coherence tomography (OCT; Cirrus HD-
OCT, Carl Zeiss Meditec, Dublin, CA). Refractive errors were
measured with an autorefractometer (ARK-7100; TOPKON,
Tokyo, Japan), and Goldmann perimetry (Haag-Streit, Bern,
Switzerland) with a V4e target was performed on all patients
who were able to cooperate. ERG followed the guidelines of
the International Society for Clinical Electrophysiology of
Vision [16].
Mutation screening: A total of 302 probands with RP were
used for the mutation screening of RHO by direct sequencing.
All variants identified in coding regions and splicing sites
were further analyzed in 114 ethnically matched controls by
sequencing. Genomic DNA was extracted from venous blood
leukocytes  using  a  FlexiGene  DNA  kit  (Qiagen,  Hilden,
Germany) according to the manufacturer's instructions. Using
the  human  rhodopsin  gene  sequence  (NT_005612),  PCR
primers were designed to amplify the coding regions of five
exons  and  flanking  intronic  regions.  All  primers  and
conditions are shown in Table 1. PCR products were purified
and  analyzed  on  an  ABI  3730  DNA  Analyzer  (Applied
Biosystems,  Foster,  CA).  All  detected  mutations  were
sequenced bidirectionally at least twice for confirmation. The
DNA mutation nomenclature is based on the cDNA sequence
with the A of the translation initiation site corresponding to
position +1.
Mutation analysis: Family segregation analysis of missense
mutations was performed when patients from at least two
generations are available in a family. Missense mutations
were also evaluated for interspecies conservation using the
ClustalX (ver. 2.0.12) multiple sequence alignment program
[17].  Six  computational  algorithms,  namely
PolyPhen,PolyPhen-2,SIFT,PMut,SNPs3D, and PANTHER,
were  used  to  predict  the  functional  impact  of  missense
mutations  identified  in  this  study.  The  PolyPhen  and
PolyPhen-2 results for each variant were classified into three
types: probably damaging, possibly damaging, and benign.
We  used  HumVar-trained  PolyPhen-2  for  distinguishing
mutations with drastic effects from other human variations,
according to the recommendation by Adzhubei et al. [18].
Both probably damaging and possibly damaging mutations
were classified as suspected pathogenic mutations. The output
of SIFT showed a normalized probability score. Positions with
TABLE 1. PRIMERS.
Target Direction Primer Sequence (5′→3′) Amplicon Tm (°C)
Exon 1 Forward TCAGAACCCAGAGTCATCCA 575 bp 58
  Reverse GGACAGGAGAAGGGAGAAGG    
Exon 2 Forward AAGCTCTCTCCTTCCCCAAG 496 bp 58
  Reverse CCAGCCCTTGTAGCAACATT    
Exon 3–4 Forward CATCCCCATCTGATCCATTC 815 bp 58
  Reverse ACTGCTGACCCAAGACTGCT    
Exon 5 Forward AGCTGGATTTGAGTGGATGG 788 bp 58
  Reverse CCTACTGTGTGCCCCATTCT    
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deleterious, and those with normalized probabilities ≥0.05
were predicted to be tolerated. In this study, “affected protein
function” was considered a suspected pathogenic mutation.
PMut  provides  a  simple  answer  with  a  reliability  index:
pathological and neutral. An output >0.5 is predicted to denote
a pathological mutation, and an output <0.5 is neutral. In
SNPs3D, two methods based on protein structure and amino
acid conservation were used to assess the functional impact
of nonsynonymous single nucleotide polymorphisms (SNPs).
A positive support vector machine score indicates a variant
classified as nondeleterious, and a negative score indicates a
deleterious  case.  A  higher  score  suggests  more  confident
classification.  Accuracy  is  significantly  higher  for  scores
greater than 0.5 or less than −0.5. PANTHER provides an
online service for the prediction of functional effects of amino
acid substitutions. The output score, the likelihood of the
transition  of  one  amino  acid  to  another,  is  the  negative
logarithm of the probability ratio of the wild-type and mutant
amino acids at a specific position. Lower scores indicate a
higher probability of a deleterious functional effect.
RESULTS
Mutation  analysis:  A  total  of  302  probands  from  Korean
families with RP were screened for mutations in RHO. By
sequencing  the  exons  and  flanking  intronic  regions,  five
heterozygous  mutations  (c.50C>T,  p.T17M;  c.533A>G,
p.Y178C; c.888G>T, p.K296N; c.893C>A, p.A298D; and c.
1040C>T, p.P347L) were identified in six probands and were
absent in 114 controls (Table 2). Of these, p.A298D has not
been  reported  previously.  The  mutation  frequencies  were
10.5% (four mutation carriers in 38 patients, 4/38) for adRP,
1.1% (2/182) for sporadic RP, and 2.0% (6/302) in total. No
mutation was detected in families with arRP and unknown
patterns  of  inheritance.  Mutations  p.Y178C  and  p.P347L
segregated with disease phenotype in studied families (Figure
1).
The  positions  of  previously  reported  mutations—
p.T17M, p.Y178C, p.K296N, and p.P347L— were highly
conserved across other species. However, in the case of the
newly identified mutation, p.A298D, there were two residues,
alanine and serine, across different species (Figure 2). To
predict  the  impact  on  protein  function  of  the  missense
mutations found in the present study, we performed an in
silico analysis using six software packages. When more than
half of the analytical results of the computational programs
suggested that a mutation was pathological, the variant was
classified  as  pathogenic.  All  five  missense  mutations,
including the newly identified p.A298D, were considered to
possibly  affect  protein  function  (Table  3).  However,  the
confidence in the prediction for the effect of p.P347L was low,
given that there was a gap at this position in many organisms.
p.Thr17Met—This  mutation  was  detected  as  a
heterozygote in one adRP proband (III-5 in Figure 1A), a 46-
year-old  male,  and  was  not  observed  in  114  ethnically
matched  controls.  The  disease  phenotype  was  transmitted
from the affected father (II-1) to his two sons (III-3 and III-5).
This position in the intradiscal region of rhodopsin is highly
conserved  among  various  organisms  (Figure  2),  and  the
substitution of threonine to methionine was predicted to affect
protein function by six prediction software (Table 3).
p.Tyr178Cys—This  mutation  was  observed  as  a
heterozygous mutation in a proband of an adRP family (II-2
in Figure 1B) and was not found in controls. This mutant allele
was  shared  between  affected  siblings  (II-2  and  II-4)  and
segregated with disease phenotype to an offspring (III-2). This
position, located in an intradiscal region, is highly conserved
(Figure  2),  and  the  substitution  was  also  predicted  to  be
pathogenic by six prediction software (Table 3).
p.Lys296Asn—This  mutation  was  detected  as  a
heterozygote in one adRP patient (II-1 in Figure 1C), a 31-
year-old female, and was not found in controls. The disease
phenotype was shared among three of five siblings (II-1, II-5,
and II-7) and was transmitted from the affected mother (II-1)
to her son (III-2). The lysine at this position in the seventh
transmembrane (TM) region of rhodopsin is highly conserved
in  all  organisms  tested  (Figure  2).  This  substitution  was
TABLE 2. MUTATION SCREENING OF THE RHO GENE.
Location Nucleotide Protein Patient Control Note Reference
Pathogenic
Exon 1 c.50C>T p.Thr17Met 1/604 0/228 Reported [30]
Exon 3 c.533A>G p.Tyr178Cys 1/604 0/228 Reported [9]
Exon 4 c.888G>T p.Lys296Asn 1/604 0/228 Reported [31]
Exon 4 c.893C>A p.Ala298Asp 1/604 0/228 Novel
Exon 5 c.1040C>T p.Pro347Leu 2/604 0/228 Reported [5]
Benign
Intron 3 c.696+4C>T   28/604 11/228 Reported rs56340615
Exon 4 c.891C>T p.Ser297Ser 5/604 2/228 Reported [31]
Intron 4 c.937–23G>A   172/604 58/228 Reported rs2071092
           Allele frequencies were measured in a total of 302 patients (604 chromosomes) and 114 controls (228 chromosomes).
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846predicted to be pathogenic by five prediction software (Table
3).
p.Ala298Asp—This mutation was newly identified in
this study. This heterozygous mutation was observed only in
a sporadic RP patient (II-3 in Figure 1D), a 55-year-old male,
and was not observed in controls. The alanine at residue 298
in the seventh TM region is conserved in most mammals, but
serine replaces alanine in chicken, frog, and zebrafish (Figure
2).  This  novel  mutation  was  predicted  to  affect  protein
function by four prediction software (Table 3).
p.Pro347Leu—This  mutation  was  detected  as  a
heterozygous mutation in a proband (I-1 in Figure 1E) of an
adRP family and was not observed in controls. In this family,
the mutation segregated with disease from the affected mother
(I-1)  to  all  four  children  (II-1,  II-2,  II-3,  and  II-4).  This
mutation was also found in a sporadic RP proband (II-3 in
Figure  1F),  a  27-year-old  female,  as  a  heterozygote.  The
proline at residue 347 in the cytoplasmic region is highly
conserved (Figure 2), and this mutation was predicted to be
pathogenic by three prediction software (Table 3).
In  the  present  study,  three  benign  single  nucleotide
variants were also detected in patients with RP. One was a
synonymous substitution at codon 297 (c.891C>T, p.S297S)
and two were identified in splicing site (c.696+4C>T, intron
3;  c.937–23G>A,  intron  4).  We  also  identified  a  novel
missense substitution (c.895G>A, p.A299T) at codon 299 in
a  normal  control.  This  nonsynonymous  change  was  not
detected in a patient with RP and was excluded from further
mutational  analysis.  Except  for  p.A299T,  there  was  no
nucleotide variant found only in controls.
Clinical  evaluation  in  retinitis  pigmentosa  patients  with
missense mutation: The RHO mutations and phenotypes are
Figure 1. Pedigrees of families in which a rhodopsin mutation was identified. The mutation p.Y178C (B) and the mutation p.P347L (E) were
segregated with disease phenotype. The newly identified mutation p.A298D (D) was found in a sporadic patient (II-3). Black and white symbols
indicate affected and unaffected individuals, respectively. The mutation is represented by “m”; wild-type alleles are represented by “+”; arrows
indicate probands.
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847summarized in Table 4. The patients ranged in age from 11 to
55 years. Most patients with missense mutations reported
difficulty with night vision starting in the first decade or early
second  decade  of  life.  Cataracts,  especially  the  posterior
subcapsular type, were evident in all patients older than 30
years of age, and both patients in their mid-forties (II-2 and
Figure 2. Conservation of rhodopsin protein. The positions of previously reported mutations (p.T17M, p.Y178C, p.K296N, and p.P347L)
were highly conserved across species. However, the position of newly identified p.A298D mutation was conserved in mammals. Accession
numbers of the protein sequences used for sequence comparison were as follows: chimpanzee, XP_516740.2; monkey, XP_001094250.1;
pig, NP_999386.1; rat, NP_254276.1; chicken, NP_990821.1; frog, NP_001080517.1; zebrafish, NP_571159.1. The arrowhead shows the
position of missense mutations identified in the present study.
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848II-4 in Figure 1B) exhibiting mutation p.Y178C had already
undergone cataract surgery.
Patients older than 40 years of age with the p.A298D or
p.P347L  mutation  showed  poor  visual  acuity  of  light
perception or no light perception in at least one eye. For one
of two patients older than 40 years of age with the p.Y178C
mutation, visual acuity was no light perception and finger
count in each eye. However, the patient with mutation p.T17M
(III-5 in Figure 1A) maintained much better visual acuity
(20/40) despite being a similar age. The fundus examination
revealed intraretinal bone-spicule pigment deposits or retinal
degeneration in all patients, except the youngest who was aged
11 (II-4 in Figure 1E). The extent of retinal pigment epithelial
atrophy,  the  number  of  retinal  pigment  deposits,  and  the
attenuation of the retinal arteries were greater in the older
individuals. Retinal pigmentary degeneration was most severe
in  a  patient  with  mutation  p.P347L  (I-1  in  Figure  1E)
compared  with  patients  of  similar  age  and  with  other
mutations (Figure 3).
All patients older than 20 years had a severely constricted
visual field, with less than the central 10° of radius remaining,
even in a 26-year-old patient with mutation p.P347L (II-3 in
Figure  1F).  An  ERG  was  extinguished  or  failed  in  older
patients because of their advanced stage or poor visual acuity.
In comparison with the four affected children in an adRP
family with mutation p.P347L, one 17-year-old patient (II-1)
showed  peripheral  constriction  of  the  visual  field  and
decreased amplitude and prolonged implicit time in a cone
ERG, whereas patients aged 15, 13, and 11 (II-2, II-3, and II-4)
showed  unremarkable  findings  in  these  tests  (Figure  1E).
However, the rod response in the ERG was extinguished or
decreased in all children. When we compared OCT findings
between a p.P347L patient (I-1 in Figure 2E) with a p.A298D
patient (II-3 in Figure 1D), severe decreases in central foveal
thickness were observed in both eyes of the p.P347L patient,
resulting  in  advanced  foveal  atrophy  (Figure  3C,D,G,H).
Interestingly, cystoid macular edema was detected by spectral
domain OCT in both eyes of all four children with mutation
p.P347L.
DISCUSSION
As  a  result  of  the  founder  effect,  mutations  can  occur
frequently in one population yet be rare or absent in another.
TABLE 3. PREDICTION OF THE FUNCTIONAL IMPACT OF MISSENSE MUTATIONS.
Mutation Phenotype PolyPhen PolyPhen2 SIFT PMut SNPs3D PANTHER
p.T17M adRP *Prob †Poss ‡A/0.00 §P/0.85 -0.56 -3.54
p.Y178C adRP Prob Prob A/0.00 P/0.71 -1.45 -4.37
p.K296N adRP Prob Prob A/0.00 P/0.72 -1.07 na
p.A298D #Sim Poss Benign A/0.00 P/0.92 -0.14 −2.58
p.P347L adRP, Sim Prob Benign A/0.00 P/0.95 na −1.92
        *Prob, probably damaging; †Poss, possibly damaging; ‡A, affect protein function; §P, pathological; #sim, simplex (sporadic) RP.
        na, not applicable. Bold means prediction of deleterious effect on protein structure or function.
TABLE 4. THE RHO MUTATIONS AND PHENOTYPES.
Patient ID Age/Sex Mutation *Onset
(y)
BCVA: RE/
LE (decimal)
Lens
opacities
VF: RE/LE ERG: Cone/Rod OCT: RE/LE
(CFT, μm)
III-5, Figure 1A 45/M p.T17M 14 0.6/0.5 NS Central/5° †na na
II-2, Figure 1B 47/M p.Y178C 16 FC/NLP IOL Failure Failure 202/188
II-4, Figure 1B 45/M p.Y178C 12 0.15/0.4 IOL na Non-detectable 282/298
III-2, Figure 1B 23/F p.Y178C 13 0.8/0.6 Clear na na 207/213
II-1, Figure 1C 31/F p.K296N 15 0.3/0.4 PSC Central/7° na na
II-3, Figure 1D 55/M p.A298D 16 HM/LP PSC Failure Non-detectable 231/267
I-1, Figure 1E 44/F p.P347L Teens LP/LP NS Failure Non-detectable 161/152
II-1, Figure 1E 17/F p.P347L 15 1.0/0.7 Clear Peripheral
constriction
Reduction/Non-
detectable
387/560
II-2, Figure 1E 15/F p.P347L 15 0.8/0.8 Clear Normal Normal range/
Non-detectable
376/428
II-3, Figure 1E 13/M p.P347L 12 1.2/1.0 Clear Normal Normal range/Non-
detectable
295/291
II-4, Figure 1E 11/M p.P347L Not yet 0.7/0.5 Clear Normal Normal range/
Reduction
400/499
II-3, Figure 1F 26/F p.P347L 23 0.6/0.7 PSC Central/10° Non-detectable 216/175
        BCVA, best corrected visual acuity; CFT, central foveal thickness; ERG, electroretinogram; FC, finger count at specified
        distance; HM, hand motion; IOL, intraocular lens; LE, left eye; LP, light perception; NLP, no light perception; NS, nuclear
        sclerosis; OCT, optical coherence tomography; PSC, posterior subcapsular opacity; RE, right eye; VF, visual field. *Onset (y),
        age at onset of night blindness. †na, data not available.
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849Figure 3. Comparison of fundus photographs and spectral domain optical coherence tomography (SD-OCT) between patients with the p.A298D
and the p.P347L mutations. Fundus photographs (A, B, E, F) show typical retinitis pigmentosa (RP) features: retinal degeneration with
pigmentation, atrophy of retinal pigment epithelium (RPE), and attenuated vessels, which involved the area inside the vascular arcade.
Compared with a 55-year-old patient with the p.A298D mutation (A, B), a 44-year-old patient with the p.P347L mutation (E, F) had more
severe retinal pigmentation, despite being 11 years younger. SD-OCT (C, D, G, H) revealed the degeneration of photoreceptor and RPE layers
and the disruption of the inner and outer segment junction of the photoreceptor in both patients. In particular, severe foveal atrophy in the
patient with the p.P347L mutation resulted in a large decrease of the central foveal thickness: 161 μm in the right eye (G; arrow) and 152
μm in the left eye (H; arrow).
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850For  example,  the  p.Pro23His  mutation  descends  from  a
common white ancestor and has not been reported in other
ethnic groups [19], including our present study. In this study,
we screened RHO mutations in Korean RP patients and found
five  missense  mutations,  including  a  novel  one.  These
missense mutations related to RP phenotype and were not
identified in ethically matched controls. The proportion of
RHO mutations that related to RP in Korean patients was
approximately 2.0% (6/302), which is lower than that in the
United States [9], and Europe [13] but similar to that in other
Asian populations, such as Japanese (5.9%) [20], Chinese
(2.0%–5.6%) [11,21], and Indian (2.0%) [6], suggesting an
ethnicity-dependent mutation rate.
The  RHO  gene  mainly  causes  adRP,  except  several
mutations that have been reported in the arRP family [22].
Generally, autosomal recessive inheritance has been assumed
to be the major cause of sporadic RP. Therefore, the finding
of heterozygous mutations of RHO (p.A298D and p.P347L)
in sporadic patients (II-3 in Figure 1D and II-3 in Figure 1F)
was unexpected. In the case of no segregation pattern among
family members, it is difficult to predict whether a newly
detected  mutation  is  pathogenic,  particularly  when  it  is  a
missense substitution. For the p.A298D mutation, which was
newly identified in a sporadic patient, we considered three
aspects for the evaluation of pathogenicity. First, we surveyed
whether the same mutation was found in normal controls.
Second,  we  analyzed  the  amino  acid  conservation  among
different species. Third, we assessed whether the alteration is
suggestive of protein malfunction by in silico analysis. The
p.A298D mutation was not observed in a panel of 114 normal
controls (228 chromosomes). In addition, the alanine residue
at  codon  298  was  relatively  well  conserved  in  mammals.
Notably,  four  different  algorithms  gave  fairly  consistent
predictions  of  pathogenicity  for  the  p.A298D  substitution
(Table 3). Although segregation analysis was not applicable,
these  results  implied  that  the  newly  identified  mutation
p.A298D may affect RHO protein structure and/or function,
thus resulting in RP.
The substitution of c.696+4C>T in the splicing donor site
of intron 3 and the substitution of c.937–23G>A in the branch
site of intron 4 were not considered to be related to RP by
affecting  pre-mRNA  splicing  because  there  were  no
significant differences in allele frequencies between patients
and controls. Interestingly, two of five missense mutations
and one synonymous change were found in the seventh TM
helix of rhodopsin. Together with p.P347L, the most common
RHO  mutation  causing  RP  worldwide,  these  positions
between codon 296 and codon 298 are thought to be a cluster
of mutation “hot spots,” at least in the Korean population.
The phenotype–genotype correlation in RP patients with
the missense mutations is also worth noting. The mode of
inheritance  is  believed  to  play  an  important  role  in
determining the prognosis of the disease. In general, adRP has
the slowest progression, while X-linked RP tends to induce
the most severe form of the disease [23,24]. Furthermore, even
within the different mutations in the same gene causing adRP,
extensive  phenotypic  variations  have  been  reported.  For
example, RHO-related RP from mutations involving codon
347 produces a more severe phenotype than RP involving
codon 23 [25]. Specifically, vision loss was estimated to occur
approximately 17 years earlier in p.P347L patients compared
with p.P23H patients [26]. We reconfirmed that Korean RP
patients carrying the p.P347L mutation experienced severe
clinical features, as has been previously reported for other
ethnic  groups  [11,26-28].  Also,  we  reconfirmed  the  mild
phenotype of the p.T17M mutation in the Korean RP patients,
which has been previously reported as a mutation with less
impaired rod and cone function in other ethnic group [29].
However,  phenotypes  of  patients  with  the  p.Y178C
mutations as well as the novel mutation p.A298D have not
been reported elsewhere. When comparing clinical features
after correcting for age, patients with the p.Y178C, p.A298D,
and p.P347L mutations exhibited worse visual acuity, while
a  patient  with  mutation  p.T17M  maintained  better  visual
acuity. When we compared a p.A298D patient with a p.P347L
patient  for  fundus  and  OCT  findings,  pigmentary
degeneration and foveal atrophy were more severe in the
p.P347L  patient  (Figure  3).  Therefore,  in  our  study
phenotypes of patients with the RHO mutations were most
severe  in  p.P347L  patients,  less  severe  in  p.Y198C  and
p.A298D  patients,  and  relatively  moderate  in  a  p.T17M
patient. However, it was not possible to statistically assess
phenotypic differences among our mutations because there
was small number of patients per each missense mutation,
with the exception of mutation p.P347L. A more accurate
description of disease severity associated with these mutations
would  require  a  longitudinal  follow-up  of  large  patient
cohorts.
In conclusion, we revealed the spectrum and frequency
of RHO mutations in Korean RP patients. RHO mutations
were found in 2.0% of Korean patients and present in sporadic
RP as well as in adRP families. Moreover, the clinical features
varied  according  to  the  mutation.  The  newly  identified
p.A298D  mutation  showed  pathological  characteristics  in
genetic  and  phenotypic  analyses.  Analysis  of  additional
families  or  identification  of  a  biochemical  defect  in  the
mutated rhodopsin is needed to confirm the role of this allele
in producing RP. This study is the largest screening of RHO
mutations in a Korean population. Understanding the unique
patterns of frequent mutations in a specific ethnic group may
facilitate  the  development  of  molecular  diagnosis  and
personalized gene therapy for RP.
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